WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018014866) CRYSTAL FORM OF DAPAGLIFLOZIN INTERMEDIATE AND PREPARATION METHOD THEREFOR
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/014866    International Application No.:    PCT/CN2017/093833
Publication Date: 25.01.2018 International Filing Date: 21.07.2017
IPC:
C07H 15/04 (2006.01), C07H 1/00 (2006.01), C07D 309/10 (2006.01), A61P 3/10 (2006.01)
Applicants: JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD. [CN/CN]; Economic and Technological Development Zone Lianyungang, Jiangsu 222047 (CN)
Inventors: LI, Xiang; (CN).
YU, Jun; (CN).
YU, Haizhou; (CN).
WANG, Jinjia; (CN).
HE, Lei; (CN).
DU, Zuyin; (CN)
Agent: GE CHENG & CO., LTD.; David W. Cheng Level 19, Tower E3, The Towers, Oriental Plaza No.1, East Chang An Avenue, Dongcheng District Beijing 100738 (CN)
Priority Data:
201610587582.7 22.07.2016 CN
Title (EN) CRYSTAL FORM OF DAPAGLIFLOZIN INTERMEDIATE AND PREPARATION METHOD THEREFOR
(FR) NOUVELLE FORME CRISTALLINE D'INTERMÉDIAIRE DE DAPAGLIFLOZINE ET SON PROCÉDÉ DE PRÉPARATION
(ZH) 达格列净中间体的晶型及其制备方法
Abstract: front page image
(EN)Disclosed are a crystal form of a dapagliflozin intermediate and a preparation method therefor, and specifically disclosed are a crystal form of the dapagliflozin intermediate (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-ethoxybenzyl)phenyl)-2-ethoxy-6-(methylhydroxyl)tetrahydro-2H-pyran-3,4,5-triol and a preparation method therefor. The advantages thereof lie in that an intermediate can be highly purified to obtain a sample with a purity of 99.3% or more, wherein same has an important significance for improving the quality of the dapagliflozin, and the preparation process is simple and suitable for industrial production.
(FR)L'invention concerne une forme cristalline d'un intermédiaire de dapagliflozine et son procédé de préparation, et plus spécifiquement une forme cristalline de l'intermédiaire de dapagliflozine (2S,3R,4S,5S,6R)-2-(4-chloro-3-(4-éthoxybenzyl)phényl)-2-éthoxy-6-(méthylhydroxyl)tétrahydro-2H-pyran-3,4,5-triol et son procédé de préparation. Les avantages de cette invention résident en ce qu'un intermédiaire peut être hautement purifié pour obtenir un échantillon d'une pureté supérieure ou égale à 99,3 %, ce qui a une importance considérable pour l'amélioration de la qualité de la dapagliflozine. En outre, le procédé de préparation est simple et approprié pour une production industrielle.
(ZH)公开了一种达格列净中间体的晶型及其制备方法,具体公开了达格列净中间体(2S,3R,4S,5S,6R)-2-(4-氯-3-(4-乙氧基苄基)苯基)-2-乙氧基-6-(甲基羟基)四氢-2H-吡喃-3,4,5-三醇的晶型及其制备方法。其优点在于,能够将中间体高度提纯,得到纯度达99.3%以上的样品,对于提高达格列净的质量有重要的意义,并且制备工艺简单,适宜工业化的生产。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)